Reliable Biopharmaceutical Corporation

Saint Louis, MO 63114

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $344K
First Award Date 04/01/88
Most Recent Award Date 08/01/02

Key Personnel

Last Name Name Awards Contact
Toce Joseph A Toce 7
Anevski Phillip J Anevski 2
Liang Bruce T Liang 1
Sampath Umashanker Sampath 1

11 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/02 - 07/31/05

DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive inotrope. ATP causes a pronounced positive inotrop...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/02 - 08/31/05

DESCRIPTION (provided by applicant): The overall objected is to develop an easy controlled method of delivery for anticancer nucleoside drugs [cytarabine (araC); cladribine] in their polymeric form as oligonucleotides. The monomer drugs, currently are delivered slowly through continuous infusion in a hospital to avoid doses-related toxicities. T...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/00 - 07/31/01

The overall objective of this project is to develop a replacement for heparin that can be orally administered. Heparin is currently the drug of choice for the prophylaxis and initial therapy of thromboembolic disease. It produces an immediate anticoagulant effect when present in ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/98 - 07/31/01

The overall objective of this project is to develop a replacement for heparin that can be orally administered. Heparin is currently the drug of choice for the prophylaxis and initial therapy of thromboembolic disease. It produces an immediate anticoagulant effect when present in ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/97 - 07/31/98

The overall objective of this project is to develop a replacement for heparin that can be orally administered. Heparin is currently the drug of choice for the prophylaxis and initial therapy of thromboembolic disease. It produces an immediate anticoagulant effect when present in ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/93 - 02/28/94

The overall objective of this project is to develop polysulfated carbohydrate derivatives that will inhibit the action of fibroblast growth factors (FGF). FGF's have been implicated in several human cancers both as angiogenic factors and as growth factors capable of sustaining autonomous cell proliferation. Inhibition of these growth factors cou...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/93 - 11/30/93

The overall objective of this project is to develop a process to produce lactobionic acid that is free of oxidizing components. Lactobionic acid is an essential component of perfusion solutions used to preserve organs for transplantation (Sumimoto, 1990). It functions as an impermeant and calcium chelator as well as a reducing agent. These so...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/92 - 05/31/93

DESCRIPTION (Adapted from applicant's abstract): The major goal of this project is to produce antisense-oligodeoxynucleotides that will readily be taken up by target cells. To accomplish this, Reliable Chemical Company proposes to attach antibiotics to antisense-oligodeoxyncleotides utilizing novel technologies. The antibiotics to be employed ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/91 - 03/31/92

DESCRIPTION (Investigator's Abstract): This is a phase I application in which the goal is to develop a therapeutic agent which would replace heparin. Although heparin is the best drug for treatment of thromboembolic disease, it is unstable if administered orally and much therefore be used by the intravenous or subcutaneous route. In addition,...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/89 - 04/30/90

Deoxynucleosides are currently playing an increasing role in medicine. Several experimental anti-viral AIDS drugs (AZT, DCC, AND DDA) are chemically modified deoxynucleosides. These drugs are expensive due to the unavailability of deoxynucleosides at reasonable costs. Deoxynucleosides are also in demand as nutrients in mammalian tissue cultur...

Load More